Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Ofatumumab a safe, effective alternative in B cell–depletion therapy

16 Apr 2018

Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus (SLE), offering an alternative to the B cell–depleting agent rituximab, according to a study.

The single-centre study included 16 patients who received ofatumumab, with 50 percent having prior exposure to cyclophosphamide and rituximab (median cumulative dose, 4 g). However, two patients were unable to complete treatment due to significant infusion reactions to ofatumumab, and were therefore excluded from the analysis.

Of the 14 patients (median age 34 years; median duration of SLE, 9.2 years), 12 achieved B cell depletion with ofatumumab. Indications were lupus nephritis (LN) in 12 patients, extra-renal flare in one and remission maintenance in the remaining patient. Treatment was associated with improvements in serological markers of disease activity, including antinuclear antibody, antidouble stranded DNA antibody and complement levels.

In the subgroup of patients treated for LN, half showed response and achieved renal remission by 6 months. Of the six nonresponders, one was retreated with ofatumumab and subsequently achieved remission, while the remaining five had progressive disease that was unresponsive to augmented immunosuppression with cyclophosphamide.

During a median follow-up of 28 months, five grade III infections were documented. No malignancies or deaths occurred.

According to researchers, ofatumumab is a potential alternative in patients who are intolerant of rituximab, with the drug proving to be safe and effective at inducing B cell depletion, with subsequent clinical responses.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.